CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Phentermine +1 moredrug
Likely dose
Phentermine 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01886937
NCT01886937Phase 4Completed

The Quantification of Ingestive Behavior

New York State Psychiatric Institute·interventional·Posted Jun 26, 2013·Updated Jul 31, 2017

In Brief

A Phase 4 clinical trial evaluating Phentermine and placebo for Obesity. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The goal of this study is to determine whether one week of phentermine compared to placebo administration results in changes in food intake during a laboratory meal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 26, 2013
Enrollment StartJul 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.0 years ago

Interventions

Phenterminedrug

After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.

placebodrug

Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.